Organic Active Ingredients TRIZ Cases

Small molecule inhibitors replace protein agents to improve stability and bioavailability while reducing toxicity in TNFα modulation.

Imidazopyridine compounds modulate iron levels in the central nervous system to reduce oxidative stress and neuronal damage.

Continuous intravenous infusion of CNDAC at 2.0 to 4.0 mg/m2 per day maintains therapeutic drug concentrations, reducing body weight suppression and leucopenia.

Prodrug compounds release active metabolites at tumor sites, improving pancreatic cancer treatment efficacy while reducing systemic toxicity.

Cyclodextrin clathrates modify water structure to enhance cellular hydration.

CD11b agonists repolarize tumor-associated macrophages to inhibit immune suppression and promote anti-tumor responses.

A tagatose and galactose syrup composition prevents crystallization through optimized concentration ratios.

N-phenyl-piperazinyl-benzenesulfonamides with specific structural variations exhibit high binding affinity to the 5-HT6 receptor.

Peptide-conjugated liposomes target collagen III-expressing cells, reducing off-target effects and improving solubility of apigenin.

Sulfur-containing polycyclic-hydroxypyridone carboxamide analogs inhibit HIV-1 replication via integrase targeting.

Substituting canonical nucleotides with non-canonical variants in synthetic RNA reduces immune response and mutation risk during delivery.

Novel 2-oxoimidazolidine-4-carboxamide compounds inhibit Nav1.8 sodium ion channel activity.

Administering recombinant nucleic acid sequences generates synthetic antibodies in vivo to neutralize antigens and induce immune responses.

Anthranilic acid derivatives inhibit the 17β-HSD3 enzyme to block testosterone biosynthesis.

Oligonucleotides avoid CpG pairs to skip exon 44 without immunogenicity, resolving the efficiency versus specificity trade-off.

A disintegrative particulate composition combines micro-fibrillated cellulose with crospovidone to enhance tablet hardness.

HPTP-beta inhibition sustains Tie-2 activation, preventing neovascularization and reducing central foveal thickness.

Distinct polymorphic structures of Compound 1 resolve formulation complexity by enabling targeted inhibition of abnormal angiogenesis in ocular diseases.

Substituted bicyclic dihydropyrimidinones overcome metabolic stability and permeability bottlenecks in current neutrophil elastase inhibitors.

Hydroxyethylcellulose increases viscosity to slow drug dissolution, masking the bitter taste of deferiprone for better patient compliance.

Fructose oligosaccharides boost serpin yields in Bifidobacterium longum, offering a non-GMO strategy to manage gluten-related disorders.

6α/β-naltrexamine analogues act as selective mu opioid receptor antagonists with improved blood-brain barrier penetration.

A rectal bile acid formulation enhances local enteroendocrine peptide secretion via targeted distal gastrointestinal delivery.

Multi-arm polymeric prodrug conjugates link taxane compounds to water-soluble carriers, reducing systemic toxicity while enhancing tumor accumulation.

A paper-based matrix delivers active ingredients through gum absorption for discrete use.

Novel N-linked macrocyclic 4-(pyrazol-5-yl)-indole compounds inhibit MCL-1 antiapoptotic activity.

Colored resin container blocks ultraviolet-visible light to protect pharmaceutical composition from degradation.

Formula II compounds inhibit Btk activity while sparing Src-family kinases to prevent adverse effects.

Bioreducible polymers with CXCR4 inhibiting moieties complex nucleic acids for targeted cellular delivery.

Steroid core compounds modulate farnesoid X receptor activity to treat metabolic diseases while avoiding cytotoxicity and off-target drug interactions.

Crystalline form CS2 of ozanimod hydrochloride resolves stability and solubility trade-offs through controlled tetrahydrofuran-water evaporation.

MYOC-specific iRNA compositions target MYOC mRNA transcripts to reduce protein levels, addressing inadequate treatments for elevated eye pressure.

Replacing ionic lubricants with non-ionic equivalents prevents acid-base reactions that convert the active salt to a free base, maintaining bioavailability.

Disubstituted pyrazole compounds inhibit ketohexokinase without carboxylic acid groups, preventing toxic acyl glucuronide formation.

Heteroaryl prodrugs utilize hydrophobic aldehyde-linked moieties to modulate solubility and enable extended drug absorption.

Triazolyl benzamide derivatives selectively target the orexin-1 receptor to treat anxiety and sleep disorders without broad systemic side effects.

A pharmaceutical composition uses polyvinyl alcohol to maintain a poorly soluble drug in an amorphous form.

Modular synthesis of Formula II and III intermediates produces HIV RT inhibitors effective against resistant mutant strains.

Formula I heterocyclic compounds inhibit mitochondrial complex I to increase reactive oxygen species in tumor cells.

A leave-on oral care composition combines hyaluronic acid and a gum-strengthening polyol to adhere to tissues.

Lysozyme and glycyrrhizic acid combination mitigates toxicity risks while delivering antiviral activity and improving intestinal barrier function.

A lozenge formulation merges potassium aluminum sulfate with Icelandic moss extract to coat oral mucosa.

Amino acid substitutions in the Fc domain extend antibody half-life, reducing administration frequency and production costs.

LC-MS/MS quantifies bile acids in dried blood spots, replacing invasive fibroblast staining to resolve diagnostic delay and sensitivity limits.

Solvent-antisolvent crystallization yields high-purity agomelatine co-crystals, resolving low yield and purity issues in commercial mass production.

Crystalline A2-73 polymorphs enhance drug bioavailability through defined XRPD patterns and controlled particle shapes.

Pd catalyzed coupling produces cinacalcet hydrochloride with defined polymorphic forms.

A multi-nutrient composition combines protein, creatine, vitamin D, calcium, and n-3 fatty acids to enhance muscle strength.